amylyx glp 1 Amylyx shores up pipeline with rights to GLP-1 antagonist Craving Reduction Comprehensive Metabolic Health Gubra initiates collaboration on new
Description
Researchers can explore retatrutide products here:
J Korean Gastric Cancer Assoc
The license grants Regeneron global rights excluding Mainland China, Hong Kong, and Macau to develop, manufacture, and commercialize the compound
Gasbjerg LS, Bergmann NC, Stensen S et al (2020) Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists
doi: 10.1016/j.ijbiomac.2022.04.107
Human and Animal Rights and Informed Consent: No animal or human subjects were used in this study by the authors
